Adding nivolumab (Opdivo) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-1 inhibitor alone significantly increased event-free survival (EFS) for patients with resectable ...
Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023. This is a video synopsis/summary of a Post Conference Perspectives involving ...
The randomized, double-blind CheckMate 77T trial, which began in 2019, included more than 450 NSCLC patients over the age of 18 from around the globe. Participants were randomized to treatment with ...
Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and ...
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of ...
It’s not a proper market showdown without all the players. And in the perioperative treatment of early-stage, non-small cell lung cancer with a PD-1/L1 inhibitor, the field is quickly taking shape.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results